Saturday 17 October 2026
Export CBUS’s income statement to Excel — free account
Cibus, Inc.
CBUS Healthcare Biotechnology
Cibus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, down 14.6% from fiscal 2024. In the quarter to June 2026, revenue grew 6.54%, EPS grew 52.5%, free cash flow grew 31.6% and total debt fell 62.1%, each against the same quarter a year earlier.
1.32
0.03
+2.33%
Follow CBUS
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 2 | 4 | 2 | 3 | 4 | 3 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(4.83) | (5.21) | (2.65) | (16.13) | (6.87) | (1.74) | 2.82 | 6.65 | 19.49 | — |
P/S ratio |
21.88 | 15.15 | 104.23 | 38.97 | 3.07 | 5.99 | 31.52 | 1,347.02 | 1,068.87 | 20.73 |
Altman Z″-Score (non-manufacturers) |
(11.34) | (11.45) | (5.41) | (36.33) | (20.02) | (8.40) | (0.78) | 4.90 | 4.08 | (5.54) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(5.93) | (4.61) | (11.13) | (1.63) | (19.20) | (11.19) | (31.66) | (48.15) | (79.65) | (4.15) |
Beneish M-Score |
(4.25) | (5.19) | — | — | — | — | — | (3.39) | (3.58) | (3.20) |
P/B ratio |
3.65 | 0.70 | 0.65 | 0.85 | 5.65 | 3.88 | 3.68 | 3.40 | 9.45 | 1.29 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.86 | 5.65 | 3.88 | 3.68 | 3.40 | 9.45 | 1.29 |
EV/Sales |
19.45 | 19.37 | 87.14 | 105.11 | 3.21 | 5.59 | 25.98 | 1,025.21 | 977.30 | 15.39 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.40) | (1.42) | (3.43) | (0.85) | (4.43) | (3.05) | (5.93) | (11.98) | (38.83) | (0.65) |
EV/FCF |
(1.38) | (1.40) | (3.13) | (0.79) | (4.32) | (2.93) | (5.43) | (10.97) | (36.60) | (0.61) |
Quick Ratio |
0.62 | 0.78 | 1.56 | 2.12 | 2.95 | 4.94 | 8.35 | 13.45 | 13.36 | 1.79 |
Current Ratio |
0.72 | 0.85 | 1.65 | 2.49 | 3.13 | 5.70 | 8.83 | 13.64 | 13.51 | 1.91 |
Net Debt/EBITDA |
(0.28) | (0.24) | 0.49 | (0.48) | (0.12) | 0.24 | 1.07 | 2.81 | 1.84 | 0.43 |
Debt/Assets |
9.79% | 8.98% | 0.12% | 59.98% | 47.07% | 30.63% | 20.71% | 15.34% | 14.06% | 0.00% |
Debt/Equity |
1.37 | 0.34 | 0.00 | 1.86 | 1.24 | 0.53 | 0.29 | 0.20 | 0.18 | 0.00 |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | 0.52 | 0.32 | 0.07 | 0.00 | 0.01 | 0.02 |
Operating CF/Net income |
0.40 | 0.23 | 0.17 | 1.15 | 0.64 | 0.97 | 0.81 | 0.72 | 0.49 | 0.76 |
Capex/Depreciation |
(0.02) | 0.00 | (0.02) | (0.99) | (0.21) | (0.96) | (1.85) | (1.71) | (1.41) | (30.21) |
Interest Coverage |
(2.75) | (7.56) | (16.88) | (257.13) | (20.74) | (49.92) | 360.66 | 106.50 | (25,789.00) | (2,421.80) |
| (222.98%) | (130.38%) | (178.00%) | (158.12%) | (114.49%) | (90.23%) | (50.82%) | (36.98%) | (73.60%) | (64.67%) | |
| (38.80%) | (56.21%) | (94.43%) | (56.67%) | (58.10%) | (59.22%) | (38.29%) | (29.22%) | (58.52%) | (56.72%) | |
ROIC |
(145.89%) | (147.93%) | (76.24%) | (81.50%) | (105.87%) | (101.92%) | (113.98%) | (100.70%) | (147.06%) | (93.51%) |
Return on Tangible Assets |
(8,410.66%) | (2,955.07%) | (901.95%) | (241.78%) | (91.08%) | (80.78%) | (49.80%) | (25.28%) | (38.46%) | (88.91%) |
Average Days of Receivables |
50.45 | 89.15 | 106.47 | 0.00 | 0.00 | 74.79 | 56.13 | 71.14 | 119.99 | 100.63 |
Research and Development Expense of Revenue |
1,214.56% | 1,183.22% | 2,331.70% | 7,358.60% | 43.62% | 46.46% | 167.39% | 4,388.98% | 2,265.35% | 1,413.03% |
Selling, General and Administrative Expense of Revenue |
739.35% | 722.60% | 1,591.30% | 6,989.81% | 59.36% | 87.16% | 349.18% | 7,624.15% | 2,911.22% | 1,671.68% |
Intangible Assets out of Total Assets |
0.87 | 0.82 | 0.86 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
225.01% | 252.23% | 885.64% | 2,546.50% | 8.04% | 20.84% | 125.75% | 1,858.05% | 2,380.31% | 237.59% |
Graham Net Nets |
(3.41) | (3.73) | (1.14) | (1.81) | (0.10) | 0.09 | 0.16 | 0.22 | 0.08 | (0.41) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(171.26%) | (387.05%) | (174.00%) | (278.20%) | (36.62%) | (31.52%) | (17.26%) | (8.69%) | (4.54%) | (0.68%) |
Free Cash Flow Yield |
(64.27%) | (91.16%) | (26.69%) | (341.35%) | (24.19%) | (31.79%) | (15.19%) | (6.94%) | (2.50%) | (121.79%) |
Revenue per Share |
0.08 | 0.18 | 0.18 | 0.17 | 34.67 | 35.20 | 11.12 | 0.38 | 1.10 | 1.02 |
Operating CF per Share |
(1.11) | (2.50) | (4.48) | (21.05) | (25.10) | (64.45) | (48.70) | (32.92) | (27.61) | (23.56) |
Capex per Share |
(0.01) | (0.03) | (0.42) | (1.65) | (0.66) | (2.64) | (4.53) | (3.01) | (1.68) | (26.59) |
Free Cash Flow per Share |
(1.12) | (2.53) | (4.90) | (22.70) | (25.76) | (67.09) | (53.22) | (35.93) | (29.29) | (50.16) |
Cash per Share |
0.22 | 0.62 | 3.17 | 3.83 | 19.11 | 43.37 | 89.92 | 153.45 | 122.36 | 12.82 |
Shareholders Equity per Share |
0.48 | 3.97 | 28.45 | 7.86 | 18.86 | 54.42 | 95.27 | 152.19 | 124.11 | 33.47 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.48 | 3.97 | 28.45 | 7.86 | 18.86 | 54.42 | 95.27 | 152.19 | 124.11 | 33.47 |
Free Cash Flow |
(51.17) | (58.85) | (50.53) | (20.88) | (19.31) | (45.46) | (34.92) | (22.05) | (13.56) | (19.66) |
Working Capital |
(4.79) | (2.93) | 13.90 | 2.47 | 10.33 | 32.65 | 56.33 | 88.52 | 53.20 | 2.60 |
Capital Expenditures |
(0.58) | (0.81) | (4.32) | (1.52) | (0.50) | (1.79) | (2.97) | (1.85) | (0.78) | (10.42) |
Net Current Asset Value |
(271.15) | (240.97) | (215.72) | (11.06) | (7.88) | 13.14 | 37.93 | 70.13 | 42.77 | 1.96 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.16 | 0.19 | 2.38 | 9.68 | 0.02 | 0.07 | 0.41 | 7.83 | 1.53 | 26.13 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
4.27 | 16.46 | 16.11 | 0.34 | 0.11 | 0.08 | 0.07 | 0.05 | 0.04 | 0.03 |
Cash ROIC |
(83.03%) | (42.63%) | (15.46%) | (86.28%) | (42.01%) | (53.07%) | (24.99%) | (10.71%) | (10.91%) | (108.35%) |
Accounts Receivable Turnover |
4.71 | 5.43 | 0.67 | 0.00 | 0.00 | 7.94 | 12.49 | 2.22 | 3.67 | 2.44 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 26.09 | 35.02 | 9.79 | 0.00 | 0.00 | 0.61 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 17.67 | 4.67 | — | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 16.10 | 9.65 | 42.36 | 0.00 | 0.00 | 651.53 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 14.37 | 102.03 | — | — | 0.00 |
Average Receivables |
0.77 | 0.79 | 2.71 | — | — | 3.00 | 0.58 | 0.11 | 0.14 | 0.16 |
Average Payables |
7.02 | 6.05 | 3.23 | 0.80 | 1.09 | 1.00 | 0.95 | 0.92 | 0.69 | 0.33 |
Average Inventory |
— | — | — | — | — | 1.99 | 1.99 | — | — | — |
Average Assets |
327.56 | 447.24 | 283.42 | 29.81 | 50.26 | 75.71 | 103.44 | 95.48 | 44.40 | 21.31 |
Average Common Equity |
56.99 | 192.81 | 150.35 | 10.68 | 25.50 | 49.69 | 77.95 | 75.44 | 35.30 | 18.69 |
Columns are period end dates